Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients

Djebbari, F.; Rampotas, A.; Vallance, G.; Panitsas, F.; Basker, N.; Sangha, G.; Salhan, B.; Karim, F.; Al-Kaisi, F.; Gudger, A.; Ngu, L.; Poynton, M.; Lam, H. P. J.; Morgan, L.; Yang, L.; Young, J.; Walker, M.; Tsagkaraki, I.; Anderson, L.; Chauhan, S. R.; Maddams, R.; Soutar, R.; Triantafillou, M.; Prideaux, S.; Obeidalla, A.; Eyre, T. A.; Bygrave, C.; Kothari, J.; Basu, S.; Ramasamy, K.

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients

Authors

Djebbari, F.

Rampotas, A.

Vallance, G.

Panitsas, F.

Basker, N.

Sangha, G.

Salhan, B.

Karim, F.

Al-Kaisi, F.

Gudger, A.

Show 10 more

Issue Date

2023-04-01

Type

Letter

Language

eng

Keywords

Humans , *Multiple Myeloma/drug therapy , *Frailty , Dexamethasone/therapeutic use , United Kingdom/epidemiology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasm Recurrence, Local/drug therapy , frailty , isatuximab , myeloma , pomalidomide , real-world

Citation

Br J Haematol. 2023 Apr;201(1):162-167. doi: 10.1111/bjh.18672. Epub 2023 Jan 31.

Publisher

Wiley

License

Journal

British journal of haematology